Investors

 

About Micromedic

 

Latest News

Micromedic: Leading the Path to Introducing Novel Cancer Diagnostic Tools
Micromedic is a publicly traded company listed on the Tel Aviv Stock Exchange (TASE: MCTC). The company focuses on the development and commercialization of cancer diagnostic products.
Since December 2011 the company is controlled by BioLight Life Sciences Investments (TASE: BOLT,OTCQX: BLGTY) realizing its clusters approach by forming a “Cancer Diagnostic Cluster”.
  28-8-2017
Invitation to general assembly meeting

27-7-2017
Micromedic Announces routine use of CellDetect in additional CLIA Laboratory in the US

28-6-2017
Micromedic announces distribution agreement in Germany

24-5-2017
Micromedic announces significant purchase order from China

6-4-2017
Announcement of the annual general assembly of shareholders of Micromedic Technologies

27-11-2016
An extraordinary assembly of Micromedic's shareholders is scheduled on January 3rd, 2017 at 4pm in the Company's offices in Kyriat Atidim

24-11-2016
Micromedic announces approval to conduct an extended clinical study with CellDetect on prostate cancer diagnosis

19-7-2016
Announcement of an extraordinary assembly of shareholders of Micromedic Technologies

26-5-2016
Announcement of the annual general assembly of shareholders of Micromedic Technologies

10-1-2016
Micromedic Announces Receipt of Regulatory Approval to Commercialize CellDetect® Bladder Cancer Monitoring Kit in Israel

29-11-2015
Micromedic Announces Cooperation with Axella Research for Financing and Execution of Clinical and Regulatory Activities Required for FDA Approval of CellDetect® Bladder Cancer Monitoring

1-9-2015
Micromedic Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of BRONJ

30-6-2015
Micromedic Obtains EU CE Mark for CellDetect® Non-Invasive Test for Detecting Recurrence of Bladder Cancer

2-2-2015
Micromedic Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence

1-7-2014
Micromedic Reports Successful Interim Results from Bladder Cancer Clinical Study

27-5-2014
Micromedic identifies new genetic markers to predict risk of developing BRONJ

3-2-2014
Micromedic reports success in clinical pilot of its Cervical Cancer diagnostic product in a central hospital in Beijing

8-7-2013
Zetiq has signed a memorandum of understanding for collaboration in India

25-12-2012
Successful interim results in a trial of a test for recurrence of bladder cancer cells in urine specimens

3-10-2012
Zetiq receives patent approval in Japan for its cell staining technology

20-11-2012
Marketing approval for Zetiq's CellDetect in China

15-4-2012
BioLight will invest 4 million NIS for additional 5% of Micromedic

27-3-2012
Micromedic signed an investment agreement with BioMarCare Technologies Inc.

25-9-2011
BioLight acquires 21% of Micromedic

Read more >>   Read more news >>
     

Stock Quotes

 

Company Materials

Exchange TASE
Symbol MCTC
ISIN IL0004330119
Stock Information English  Hebrew

Leaflet CellDetect Bladder


Leaflet CellDetect Technology
Read more >>    
     
For more information please contact Mr. Itai Bar-Natan, CFO at Itai@m-medic.com
 
 
© Micromedic Technologies Ltd. site mapcontact
 
Site by Site2goal | Design Studio Michal Lehavi